We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck to Launch New Late-Stage Trial of Experimental COVID-19 Treatment
Merck to Launch New Late-Stage Trial of Experimental COVID-19 Treatment
Merck is planning to launch a new late-stage trial of an experimental COVID-19 treatment, MK-7110 (CD24Fc), because the previous phase 3 study enrolled too few participants to support regulatory clearance from the FDA.